KIT and neoplasm: Lenvatinib inhibits VEGF receptors 1–3, platelet-derived growth factor receptor-α, fibroblast growth factor receptors (FGFR) 1–4, KIT, and RET, among which inhibition of VEGF receptor 2 contributes to the major pharmacological effect, including the inhibition of tumor neoangiogenesis.